Passage BIO, Inc. (PASG) stock
Close on Nov 11, 2026Market cap $12.87MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $12.87M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 257.43
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$33.08M
- EPS, diluted
- -$10.35
- Book value per share
- $0.02
- Diluted shares
- 3M
Trading
- Previous close
- $3.78
- Open
- $3.71
- Day's range
- $3.71 – $4.00
- Volume
- 27,915
- Average volume (20 days)
- 15,595
- Beta (5 years)
- 1.64
- 52-week range
- $3.29 – $20.00
- RSI (14 days)
- 55.4
- Volatility (1 year)
- 115.7%
- Relative volume
- 1.15×
- WACC
- 13.1%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PASG | S&P 500 | Difference | PASG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.4% | -2.4% | +10.8 pts | ||
| 3 months | -11.1% | -1.2% | −10.0 pts | ||
| Year to date | -66.1% | +12.3% | −78.4 pts | ||
| 1 year | -48.1% | +12.4% | −60.5 pts | ||
| 3 years | -66.7% | +78.8% | −145.5 pts | -30.7% | +21.4% |
| 5 years | -97.7% | +75.2% | −172.8 pts | -52.8% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Passage BIO filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Results
- Results
About Passage BIO
Biological Products, (No Diagnostic Substances)
Passage Bio is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases of the central nervous system. The company specializes in one-time adeno-associated virus (AAV) gene therapies designed to address underlying disease pathologies. Its lead product candidate is PBFT02, a gene replacement therapy delivered via intra cisterna magna administration to elevate progranulin levels. PBFT02 is in clinical trials for frontotemporal dementia caused by progranulin deficiency and frontotemporal dementia associated with C9orf72 mutations, with potential application in amyotrophic lateral sclerosis and Alzheimer’s disease. Additionally, the company conducts a preclinical program targeting Huntington’s disease.
Company profile, executives and historyPassage BIO stock: common questions
What is Passage BIO's stock price?
PASG closed at $4.00 on Nov 11, 2026, up 5.82% on the day. Over the past 52 weeks it traded between $3.29 and $20.00.
What is Passage BIO's market cap?
Passage BIO was worth $12.87M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PASG's P/E ratio?
Passage BIO lost money over the twelve months to Sep 30, 2026 (diluted EPS -$10.35), so it has no meaningful P/E ratio.
Does Passage BIO pay a dividend?
No. Passage BIO has not paid a cash dividend over the last twelve months.
How has PASG stock performed over the past year?
Including dividends, PASG returned -48.1% over the past year, against +12.4% for the S&P 500.
How many PASG shares are sold short?
0M shares were sold short at the latest FINRA report, 2.13% of the float, or 4.0 days of average trading volume.
Who are Passage BIO's competitors?
Companies most similar to Passage BIO by business, industry and size include VYGR, DNLI, ALEC, CGTX, ABOS.
See a number that looks wrong?